Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Biocon's chairperson urges India's government to exempt cancer and chronic disease drugs from taxes to alleviate patient ...

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...